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Abstract
Aims: The aim of this study was to compare the 5-year outcomes of patients with multivessel disease (MVD)
involving the proximal left anterior descending (LAD) artery who were treated with sirolimus drug-eluting
stents (SES), bare metal stents (BMS) and coronary artery bypass surgery (CABG).
Methods and results: Clinical outcomes were compared between the 682 patients enrolled in the ARTS-I
and ARTS-II study who had MVD involving the proximal LAD, and were treated with BMS (27.4%), CABG
(30.2%), and SES (42.4%). At 5-year follow-up the primary endpoint of major adverse cardiovascular and
cerebrovascular events (MACCE) occurred in 33.7%, 18.0% and 24.9% of patients treated with BMS,
CABG and SES, respectively (BMS vs. SES p=0.04, CABG vs. SES p=0.07). Unadjusted and adjusted rates
of mortality and death/stroke/myocardial infarction (safety) were comparable between all three treatments.
Repeat revascularisation was significantly lower following CABG irrespective of adjustment. The absolute
difference in MACCE between patients with a logistic EuroSCORE above and below the mean (i.e., 2.09%)
was 18.8% (p=0.001), and 1.9% (p=0.28) for CABG and SES, respectively. In patients with a high
EuroSCORE, SES was a significantly safer treatment (p=0.04) whilst repeat revascularisation remained
lower with CABG irrespective of the EuroSCORE.
Conclusions: At 5-year follow-up CABG has comparable safety, and superior efficacy in terms of reducing
repeat revascularisation compared to BMS and SES in the treatment of patients with MVD involving the
proximal LAD however, appropriate patient selection remains imperative.
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Introduction
The proximal segment of the left anterior descending (LAD) artery is
the most important segment of the coronary tree after the left main
stem (LMS). Its importance is highlighted by the poor prognosis if
left untreated,1 and the recent appropriateness guidelines for
revascularisation from the American Heart Association/American
College of Cardiology (AHA/ACC), which do not deem revascularisation
of the proximal LAD inappropriate, even if it is present in isolation, or
associated with no symptoms in patients on little, or no therapy.2
The optimal method of revascularisation in patients with multivessel
disease (MVD) (with or without involvement of the proximal LAD)
continues to remain a contentious issue.3 Although patients with
MVD have preferentially been treated with coronary artery bypass
grafting (CABG), no survival advantage has ever been demonstrated
in randomised trials comparing CABG to percutaneous coronary
intervention (PCI) with either bare metal stents (BMS) or drug-
eluting stents (DES).4-6 Moreover, recent evidence suggests that PCI
with DES offer a safe and suitable alternative to CABG in specific
groups of patients with MVD.6-7
In patients with MVD with proximal LAD involvement previous
observational studies have demonstrated a prognostic advantage
following revascularisation with CABG compared to balloon
angioplasty, or PCI with BMS.8-10 This benefit however, has not been
reproduced in the sub-group analyses of patients with proximal LAD
lesions enrolled in randomised studies of MVD comparing BMS to
CABG.11,12 Moreover, in this group of patients the data on the use of
DES, which offer the advantage of reduced rates of restenosis
compared to BMS,13 is limited by the availability of only medium
term outcomes.14-16
The Arterial Revascularisation Therapies Part I (ARTS-I) and Part II
(ARTS-II) studies both recruited patients with MVD using the same
inclusion criteria.17-18 In the ARTS-I study patients were randomised to
treatment with a BMS or CABG, whilst in the single arm ARTS-II study all
patients received a sirolimus eluting stent (SES). The 3-year outcomes of
682 patients with proximal LAD disease from the ARTS-I and ARTS-II
study have been published previously.14 The aim of this report was to
describe the 5-year outcomes (i.e., major adverse cardiovascular and
cerebrovascular events – [MACCE]) of this important pre-specified sub-
group of patients, which consequently represents the longest reported
follow-up of proximal LAD disease treated with DES.
Methods
Study population
The ARTS-I and ARTS-II studies have been published previously.17,18
In brief, the multicentre ARTS-I study randomised 1,205 patients
between April 1997 and June 1998 to treatment with PCI with a BMS
or CABG. The ARTS-II study was a multicentre, non-randomised, open
label trial which recruited 607 patients between February and
November 2003 who were all treated with PCI using a SES.
Patient selection
The inclusion and exclusion criteria for both studies were the same.
Patients with stable angina, unstable angina or silent ischaemia, who
had ≥2 coronary lesions, located in different major epicardial vessels
and/or their side-branches (not including the LMS) that were
potentially amenable to stent implantation were eligible for inclusion.
All patients were required to have a lesion with a diameter stenosis
>50% in the LAD, and ≥1 other major epicardial coronary artery.
The goal was to achieve complete anatomic revascularisation. There
was no restriction on the total implanted stent length. Decisions to
place stents in lesions with bifurcations, fresh thrombus, calcification,
diffuse disease, complex anatomy or stenting of side branches were
left to the discretion of the operators. By protocol surgical
revascularisation was performed “on-pump”, and where possible the
left internal mammary artery graft was used for LAD revascularisation.
The major exclusion criteria were: patients with previous PCI, LMS
disease, overt congestive heart failure, left ventricular ejection fraction
<30 percent, history of a cerebrovascular accident (CVA), transmural
myocardial infarction (MI) in the preceding week, severe hepatic or
renal disease, neutropenia or thrombocytopenia, an intolerance or
contraindication to acetylsalicylic acid or thienopyridines, the need for
concomitant major surgery and life-limiting major concomitant non-
cardiac diseases. Written informed consent was obtained from each
patient prior to enrolment, and the study was approved by the ethics
committee of each participating site.
The five year outcomes of the ARTS-I and ARTS-II patient cohorts
have already been published elsewhere.19,20 This pre-specified sub-
group analysis included only those patients with a >50% diameter
stenosis lesion in the proximal LAD, defined as the coronary
segment between the branching point of the LMS and the first
major septal branch (segment 6 in the AHA classification).21
Endpoints
The primary endpoint of this study was MACCE, defined as a
composite of death, stroke, MI and repeat revascularisation
(percutaneous or surgical) at 5-year follow-up. Secondary endpoints
included death, stroke, MI, safety (a composite of death, stroke and
MI) and repeat revascularisation at 5-year follow-up.
Definitions
Deaths included mortality from any cause. Cerebrovascular
accidents included transient ischaemic attacks, reversible
neurological deficits, intracranial haemorrhage, and ischaemic
stroke.17 MI was defined in the first seven days after the
intervention, if there was documentation of new abnormal Q-waves
and either a ratio of serum creatinine kinase MB (CK-MB)
isoenzyme to total creatinine kinase (CK) that was ≥0.1, or a CK-MB
value that was five times the upper limit of normal. Serum CK and
CK-MB isoenzyme concentrations were measured 6, 12, and
18 hours after the intervention. Commencing eight days after the
intervention (the length of the hospital stay after surgery), either
abnormal Q-waves or enzymatic changes were sufficient for
a diagnosis of MI. An MI was only confirmed after the relevant
electrocardiograms had been analysed by the core laboratory and
adjudicated by the clinical-events committee. This two-part method
of defining MI was developed for ARTS-I to address the difficulty in
diagnosing an MI after cardiac surgery.17 The incidence of stent
thrombosis according to the Academic Research Consortium
definitions was only available for patients in ARTS-II.22
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Statistical methods
Continuous variables are expressed as mean±standard deviation (SD)
and were compared using the unpaired Student’s t-test. Categorical
data are presented as percentages, and were compared using the χ2
test or Fischer’s exact test. Survival curves were constructed for time-
to-event variables using Kaplan-Meier estimates, and compared by
the log-rank test. Patients lost to follow-up were considered at risk
until the date of last contact, at which point they were censored. The
overall association between treatment type and MACCE was further
examined using univariate and multivariate Cox proportional hazard
models. In the multivariate model, to compensate for difference in
baseline and procedural characteristics between patients enrolled in
ARTS-I and ARTS-II adjustments were made for the potential
confounders of gender, logistic EuroSCORE (EUROLOG), smoking
status, diabetes, hypercholesterolaemia, hypertension, and previous
myocardial infarction. Finally patient outcomes were also stratified
into two groups according to the mean value of the EUROLOG. A p
value of <0.05 was considered significant, and all tests were two-
tailed. Data were analysed with SPSS version 17.0 software (SPSS
Inc., Chicago, IL, USA).
Results
The ARTS-I study recruited 1,205 patients, of whom a total of 393
(32.6%) had involvement of the proximal LAD. The ARTS-II study
enrolled 607 patients, of whom 289 (47.6%) had proximal LAD
disease. In total there were 682 patients in this sub-group analysis
of whom 187 (27.4%), 206 (30.2%), and 289 (42.4%) received
treatment with BMS, CABG and SES, respectively.
Baseline angiographic characteristics (Table 1)
Baseline angiographic characteristics of the study population,
stratified according to method of revascularisation, have been
published previously, and are summarised in Table 1.11,14 As
expected considering the time lag between the two studies the
incidence of risk factors was significantly higher in the cohort treated
with SES. Despite this however, the overall risk as assessed using the
EuroSCORE (additive or logistic) was similar for each treatment group.
Angiographic and lesion characteristics (Table 2)
The characteristics of the proximal LAD lesions are shown in
Table 2. Patients treated with SES had significantly more complex
lesions as indicated by the longer lesion length, and greater
proportion of Type C lesions, calcified lesions and bifurcations when
compared with those treated with BMS or CABG. The
characteristics of coronary lesions in segments other than in the
proximal LAD are presented elsewhere.14 Overall patients treated
with SES had more extensive disease, and significantly lower rates
of complete revascularisation compared to those treated with BMS
or CABG. Patients receiving CABG had the longest hospital stay.
Table 1. Baseline patient characteristics.
Variable (%) unless stated ARTS-II SES ARTS-I BMS ARTS-I CABG
(N=289) (N=187) (N=206)
Baseline characteristics
Male gender 80.6 78.1 181.1
Age, years 63.0±10.2 60.1±9.5¶ 62.0±9.0
Body mass index, kg/m2 27.5±4.1 26.9±3.6 27.4±3.4
Risk factors
Previous myocardial infarction 32.5 44.4¶ 37.9
Diabetes 24.9 11.2¶ 14.6¶
Hypertension 65.7 41.2¶ 44.2
Hypercholesterolaemia 74.0 63.1¶ 58.5
Current smoker 17.6 27.4¶ 20.4
Peripheral vascular disease 8.0 5.3 5.3
Chronic obstructive 
airways disease 4.8 6.4 4.4
EuroSCORE
Additive 2.49±2.02 2.22±1.87 2.28±1.78
Logistic (%) 2.23±1.67 1.99±1.40 1.98±1.31
Ejection fraction 59.2±11.5 60.8±12.2 60.5±13.3
Indication for treatment
Stable angina 57.4 53.5 59.7
Unstable angina 32.9 41.7 34.5
Silent ischaemia 9.7 4.8 5.8
¶ p<0.05 vs. ARTS-II SES group; SES: sirolimus eluting stent; BMS: bare
metal stent; CABG: coronary artery bypass graft surgery
Table 2. Angiographic and procedural characteristics.
Variable (%) unless stated ARTS-II SES ARTS-I BMS ARTS-I CABG
(N=289) (N=187) (N=206)
Proximal LAD lesion characteristics
Ostial LAD 17.4 26.2 21.4
Lesion Length(visual)
Discreet (<10mm) 49.8 64.2¶ 69.9¶
Tubular (10-20mm) 25.4 25.1 27.2
Diffuse (>20mm) 22.0 6.4¶ 1.0¶
Lesion classification
Type A 3.1 1.1 7.3¶
Type B1 11.9 20.9¶ 21.8¶
Type B2 61.9 68.9 70.6
Type C 23.1 7.5¶ 1.9¶
Moderate/heavy calcification 59.9 36.7¶ 27.7¶
Thrombus containing lesions 0.0 2.8 1.0
Eccentric lesion 86.8 86.1 80.6
Occlusion 0.0 3.2 1.0
Bifurcation requiring
double wiring 51.2 42.8 39.3¶
Additional disease characteristics
No. of diseased vessels 2.5±0.5 2.3±0.5¶ 2.3±0.5¶
No. of diseased lesions 
with stenosis > 50% 3.7±1.3 3.0±1.0¶ 3.0±1.1¶
Extent of other coronary disease
Two-vessel disease 45.3 67.4¶ 60.2¶
Three-vessel disease 54.0 29.4¶ 36.9¶
Location of other lesions (% of all lesions)
Circumflex artery 28.5 29.3 29.0
Right coronary artery 28.6 24.3 25.7
Procedural characteristics
Total number of stents
implanted 3.8±1.6 2.9±1.2¶ –
Total stent length, mm 73.9±33.4 48.3±21.5¶ –
Number of anastomoses – – 3.0±1.0
Left internal mammary 
graft use – – 94.5
Completeness of 
revascularisation 57.7 70.1¶ 87.1¶
Length of hospital stay, days 3.56±2.68 3.80±3.60 9.76±4.74¶
¶ p<0.05 vs. ARTS-II SES group; No.: number; LAD: left anterior descending
artery; SES: sirolimus eluting stent; BMS: bare metal stent; CABG: coronary
artery bypass grafting
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Outcomes at 5-years (Table 3, Figure 1)
The hierarchical and non-hierarchical outcomes at 5-years follow-up
are shown in Table 3, whilst unadjusted Kaplan Meier survival curves
are shown in Figure 1. Overall there was a significant reduction in the
primary endpoint of 5-year MACCE following treatment with SES
compared to BMS (Relative risk [RR] 1.35, 95% CI [1.02-1.80],
p=0.04), whilst only a trend towards a lower incidence of MACCE was
seen amongst those treated with CABG compared to SES (RR 0.72,
95% CI [0.51-1.03], p=0.07). In general, safety was comparable
between all three treatments modalities.
Figure 1. Kaplan Meier survival curves at 5-year follow-up for (A) death (B) death/stroke/myocardial infarction (C) any repeat revascularisation and
(D) major adverse cardiovascular and cerebrovascular events (MACCE) for treatment with sirolimus eluting stents (SES), bare metal stents (BMS)
and coronary artery bypass surgery (CABG).
Table 3. Unadjusted clinical outcomes at 5-year follow-up.
Variable (%) unless stated ARTS-II SES ARTS-I BMS ARTS-I CABG SES vs. BMS SES vs. CABG
(N=289) (N=187) (N=206)
Hierarchical events
Death 3.5 7.0 6.3 2.00[0.90-4.49] p=0.08 1.82[0.82-4.08]p=0.14
Cerebrovascular accident 2.8 2.1 1.5
Myocardial infarction 4.5 5.9 4.9
Q-wave 2.1 4.3 4.4
Non-Q-wave 2.4 1.6 0.5
Death/CVA/MI 10.7 15.0 12.6 1.18[0.91-1.52] p=0.17 1.08[0.84-1.39] p=0.52
Repeat revascularisation 14.2 18.7 5.3
PCI 11.1 12.8 4.9
CABG 3.1 5.9 0.5
Any MACCE 24.9 33.7 18.0 1.35[1.02-1.80] p=0.04 0.72[0.51-1.03] p=0.07
Non-hierarchical
Cerebrovascular accident 3.1 2.7 1.9 0.86[0.29-2.52] p=0.78 0.62[0.20-2.00] p=0.42
Myocardial infarction 4.5 7.5 6.8 1.66[0.80-3.46] p=0.17 1.51[0.73-3.15] p=0.27
Q-wave 2.1 5.3 6.3 2.58[0.95-6.97] p=0.053 3.04[1.18-7.87] p=0.02
Non-Q-wave 2.4 2.1 0.5 0.88[0.26-2.98] p=0.84 0.40[0.08-1.91] p=0.23
Repeat revascularisation 18.3 25.1 6.8 1.37[0.97-1.94] p=0.08 0.37[0.21-0.65] p<0.001
PCI 15.2 20.9 6.3 1.37[0.93-2.02] p=0.11 0.41[0.23-0.75] p=0.002
CABG 3.5 7.0 0.5 2.00[0.90-4.49] p=0.08 0.14[0.02-1.00] p=0.03
PCI: percutaneous coronary intervention; CABG: coronary artery bypass grafting; CVA: cerebrovascular accident; MI: myocardial infarction; MACCE: major
adverse cardiovascular and cerebrovascular events; BMS: bare metal stent; DES: drug-eluting stent
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The 5-year outcomes between patients treated with CABG and SES
stratified according to a EUROLOG above or below the mean of
2.09% is shown in Figure 2. The absolute difference in MACCE for
patients treated with CABG, and SES between those with low and
high EUROLOG was 18.8% (p=0.001), and 1.9% (p=0.28),
respectively, which was primarily driven by the increased incidence
of death/CVA/MI in those patients with high EUROLOG. Repeat
revascularisation remained lower with CABG irrespective of
EUROLOG; in addition, within each treatment group there was no
significant difference in rates of repeat revascularisation between
patients with high or low EUROLOG.
Figure 3 shows the univariate and multivariate Cox proportional
hazard models for outcomes between SES and CABG at 5-year
follow-up. After adjusting for confounding factors, rates of mortality,
the composite of safety, and the composite of MACCE remained
comparable between SES and CABG. Of note, even after
adjustment CABG remained the most effective treatment in terms of
reducing repeat revascularisations.
Figure 3. Unadjusted ( ) and adjusted (  ) Hazard ratios at 5-years
 follow-up between treatment with sirolimus eluting stents (SES) and
coronary artery bypass surgery (CABG). Hazard ratios were adjusted for
gender, logistic EuroSCORE, smoking status, diabetes, hypercholes-
terolaemia, hypertension, and previous myocardial infarction.
*Adjusted for, gender, logistic EuroSCORE, smoking status, diabetes,
hypercholesterolaemia, hypertension, and previous myocardial infarc-
tion.
Figure 2. Kaplan Meier survival curves at 5-year follow-up up for (A)
death/stroke/myocardial infarction (B) any repeat revascularisation and
(C) major adverse cardiovascular and cerebrovascular events (MACCE)
for treatment with sirolimus eluting stents (SES), and coronary artery
bypass surgery (CABG) stratified according to patients with a logistic
EuroSCORE above (dotted line) or below (solid line) 2.09%.
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Stent thrombosis
Definite stent thrombosis according to ARC definitions occurred in
2.8% of the ARTS-II proximal LAD patients (early 0.7%; late 0.3%;
very late 1.7%), while the composite of definite or probable stent
thrombosis occurred in 6.6% (early 1.4%; late 0.7%; very late
4.5%).
Discussion
The main findings from this study are that in patients with MVD
involving the proximal LAD, overall long-term safety outcomes are
comparable following treatment with SES, BMS, or CABG.
Moreover, this study also demonstrates that in this complex group of
patients CABG remains the most effective treatment in terms of
reducing repeat revascularisation out to 5-year follow-up.
The proximal LAD occupies an important location in the coronary
arterial tree, and as such it is no surprise that untreated lesions in
this location are associated with poor outcomes.1 Its importance is
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further reflected by recommendations that revascularisation of any
significant proximal LAD lesions, even in the absence of symptoms,
is not deemed inappropriate.2
Proximal LAD disease can occur in isolation or in association with
MVD. The former has been the subject of numerous randomised
controlled trials, which have compared PCI using BMS, to
surgical revascularisation by standard CABG or minimally
invasive direct CABG with a LIMA-to-LAD anatomosis.23-25 Meta-
analysis of these studies report similar survival between groups
out to 5-year follow-up, and reduced repeat revascularisation
with CABG.
In the setting of MVD, data is confined to retrospective studies, and
long-term outcome (>3 years) data is limited.9-12,14-16 In general
there is little dispute over the superiority of DES over BMS in terms
of reducing rates of target lesion revascularisation (TLR).13 For
lesions in the proximal LAD however, the issue is complicated by the
proximal LAD having a normal mean minimum lumen diameter of
approximately 3 mm,26 the cut off above which DES have been
shown to offer only limited clinical benefit.27 Consistent with this,
Bonello et al recently reported no significant difference in MACE or
TLR at 1-year follow-up among 487 patients with MVD and non-
ostial proximal LAD lesions, treated with BMS or DES (mean stent
diameter 3.2 mm).15 In contrast to these results, the current study
demonstrates not only comparable safety, but also a significant
reduction in repeat revascularisation (p[log-rank]=0.04) and overall
MACCE (p[log-rank]=0.02) out to 5-years with the use of DES
compared to BMS.
In this the sub-group of patients with MVD and proximal LAD
lesions, treatment with CABG has shown a consistent benefit in
terms of reduced repeat revascularisation compared to balloon
angioplasty, and PCI with either BMS or DES.9-12,14,16,28 With respect
to safety, there have been conflicting results. The majority of the
data comes from sub-group analyses of the New York State registry,
and results demonstrate a consistent and significant improvement
in adjusted survival out to 3-years follow-up after treatment with
CABG compared to balloon angioplasty or stenting with BMS.9,10 In
contrast however, comparable safety was seen in this group of
patients in the sub-group analysis of the randomised ARTS-I
study.11
Similar inconsistent results have also been seen in the more recent
observational studies which have included patients treated with
DES. Yan et al recently reported comparable adjusted mortality at 2-
year follow-up between DES and CABG,16 whilst Hannan et al
demonstrated no difference in unadjusted survival between groups,
however following adjustment, outcomes were superior following
CABG.28 In addition, Kukreja et al reported the 3-year outcomes
from the current cohort and showed significantly improved
unadjusted survival following SES implantation. This benefit has not
been maintained out to 5-years, and is likely to reflect the larger
absolute increase in death (SES ∆2.4%, CABG ∆1.0%) and MI
(SES ∆2.8%, CABG ∆1.0%) between 3- and 5-years follow-up
observed in patients treated with SES compared to CABG. It is more
than likely that these events were driven by definite/probable stent
thrombosis which rose by 73% in this cohort between 3- and 5-year
follow-up.
One of the limitations of these previous observational studies is the
difficulty in effectively adjusting outcomes according to different
baseline clinical and angiographic variables.29 In daily practice, this
heterogeneity reiterates the importance of appropriate patient
selection when deciding individualised revascularisation strategy in
patients with MVD.6,7 Historically CABG has been the preferred
method of revascularisation in these patients; however it is now
apparent that in select patients, PCI is a safe and effective
alternative.6 In the current study the EUROLOG identified those
patients who were at highest risk of adverse events following
treatment with either CABG or PCI. Most importantly, in those
patients with a high EUROLOG, PCI offered a significantly safer
treatment, and an improved MACCE free survival compared to
CABG. This is in keeping with previous published data which have
indicated that the EuroSCORE has a role to play in risk stratification
amongst patients undergoing revascularisation by either PCI or
CABG.30,31
In contrast to this patient based risk assessment, assessment of
coronary anatomy, using for example, the SYNTAX score, is also of
vital importance.32 Studies indicate that the SYNTAX score can help
aid revascularisation decisions; however it also has an increasingly
important role in patient risk stratification.6,7,33,34 Importantly the
calculation of the SYNTAX score requires a careful and through
review of the coronary angiogram. This may identify those patients
in whom completely revascularisation with PCI cannot be achieved,
which can have significant implications on overall outcome.35 In the
current cohort complete revascularisation was accomplished in only
57.7% of patients in the SES group, compared to 87.1% (p<0.05)
of those treated with CABG. In additional incomplete revascularisation
was a univariate predictor of MACCE in patients treated with SES
(HR:1.65, 95% CI:1.02-2.66, p=0.04). These results reiterate the
importance of a comprehensive risk assessment to ensure that
patients receive the most appropriate tailored revascularisation
strategy, which takes into consideration their comorbidities and
coronary anatomy.36,37
Limitations
The current study is limited by the long time lag between the
enrolment of patients in ARTS-I and ARTS-II, which may have
influenced outcomes. The development of new surgical techniques
and increasing use of arterial conduits may of lead to improved
surgical outcomes if the CABG patients had been enrolled at the
same time as ARTS-II patients. Conversely the patients in ARTS-II
had a worse baseline and procedural risk profile compared to those
included in ARTS-I, however better stent design, improved PCI
technique and equipment, as well as the advances in
pharmacological therapy probably account for the overall improved
outcomes. In addition ARTS-II was a registry, and as such suffers
from the inherent limitation of this type of study. Moreover, this
cohort represents a sub-group analysis and therefore endpoints
were not adequately powered to provide definitive results. Leaving
these study design limitations aside, the absence of SYNTAX scores
in patients treated with CABG is a limitation which otherwise would
have allowed a more effective comparison of anatomical complexity.
Unfortunately the angiographic films for ARTS-I are unavailable.
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Conclusion
At 5-years follow-up surgical revascularisation remains the most
effective treatment in terms of reducing repeat revascularisation in
patients with MVD involving the proximal LAD. Safety at 5-year follow-
up is comparable overall; however in those patients with a high
EUROLOG, SES appears to provide a safer alternative to CABG. These
results reiterate that appropriate patient selection, taking into account
both anatomical and clinical variables is imperative when determining
the optimal revascularisation strategy in these complex patients.
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